• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gain Therapeutics, Inc. - Common Stock (NQ:GANX)

1.680 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gain Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering
July 16, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
July 16, 2025
Via Benzinga
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus
July 16, 2025
U.S. stock futures swung between gains and losses on Wednesday after ending on a mixed note on Tuesday. Futures of major benchmark indices were mixed. 
Via Benzinga
Topics Economy
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket
July 16, 2025
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
July 15, 2025
Via Benzinga
Tuesday's after hours session: top gainers and losers
July 15, 2025
The regular session of the US market on Tuesday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
Gain Therapeutics Announces Proposed Public Offering
July 15, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
June 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate in Upcoming Investor Conferences
June 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
May 29, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update
May 14, 2025
First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected Mid-2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
May 12, 2025
GT-02287 protects dopaminergic neurons against mitochondrial toxin MPP+ suggesting an action on mitochondrial GCase in addition to its improvement of lysosomal GCase activity 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics to Participate at The Citizens Life Sciences Conference
May 01, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
April 30, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update
April 10, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
April 01, 2025
Via Benzinga
Gain Therapeutics Announces Poster Presentation at AD/PD 2025
March 28, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update
March 27, 2025
First Analysis from Phase 1b Study of GT-02287 in Parkinson’s Disease Expected in Q2 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
Via Get News
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's Disease
March 14, 2025
Via ACCESS Newswire
Gain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s Disease
March 14, 2025
Interim Analysis Expected End of 2Q 2025 
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Oral Presentation at AD/PD 2025
March 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
February 06, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Participate in Upcoming Investor Conferences
February 05, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Announces Formation of Clinical Advisory Board to Support Continued Advancement of Lead Drug Candidate GT-02287
January 08, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director
January 07, 2025
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson’s Disease
December 23, 2024
From Gain Therapeutics, Inc.
Via GlobeNewswire
Gain Therapeutics To Present At Biotech Showcase 2025
December 11, 2024
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform 
From Gain Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
November 15, 2024
Via Benzinga
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update
November 14, 2024
Initiation of Phase 1b Study of GT-02287 in Parkinson’s patients expected by end of 2024 
From Gain Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap